Amivantamab plus Chemotherapy in NSCLC with

Publication Title

The New England journal of medicine

Document Type

Article

Publication Date

11-30-2023

Keywords

Humans; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exons; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Carboplatin; Pemetrexed; Antineoplastic Agents, Immunological; oregon; chiles

Abstract

BACKGROUND: Amivantamab has been approved for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (

METHODS: In this phase 3, international, randomized trial, we assigned in a 1:1 ratio patients with advanced NSCLC with

RESULTS: A total of 308 patients underwent randomization (153 to receive amivantamab-chemotherapy and 155 to receive chemotherapy alone). Progression-free survival was significantly longer in the amivantamab-chemotherapy group than in the chemotherapy group (median, 11.4 months and 6.7 months, respectively; hazard ratio for disease progression or death, 0.40; 95% confidence interval [CI], 0.30 to 0.53; P

CONCLUSIONS: The use of amivantamab-chemotherapy resulted in superior efficacy as compared with chemotherapy alone as first-line treatment of patients with advanced NSCLC with

Clinical Institute

Cancer

Specialty

Oncology

Specialty

Pulmonary Medicine

Specialty

Pharmacy

DOI

10.1056/NEJMoa2306441

Share

COinS